MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Ascendis Pharma A/S (NASDAQ: ASND)
Organization & Developments: Ascendis
Parents
Ascendis Pharma A/S (NASDAQ: ASND)
Children
2012: United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension (2012)
2017: The Investment Case For Ascendis Pharma_seekingalpha.com
2019: Ascendis Pharma: Updates To Thesis, Q4 Data Looms_seekingalpha.com
2019: Ascendis Proves Technology Platform With Big Win In Major Indication_seekingalpha.com
2020: Ascendis Pharma: TransCon Platform Is A Major Value Driver
2022: Ascendis Pharma: Translating Valuable IP Into A Profitable Business_ seekingalpha.com
2023: Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For_ seekingalpha.com
2023: Ascendis’ shares slump 38% as FDA unexpectedly halts hypoparathyroidism drug review
2024: Ascendis Challenges BioMarin, But Market Response Seems Excessive_ seekingalpha.com
2024: Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up
2024: Ascendis Pharma's Ambitious Vision 2030: seekingalpha.com
2024: Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
2025: Ascendis Pharma: Danish Blockbuster Hunter
2025: Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)_ seekingalpha.com
2025: Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade
Jumps
*Key People: Ascendis
Finance & Acquisitions: Ascendis